Review Article
Antivascular Therapy for Epithelial Ovarian Cancer
Table 2
Ongoing trials with multitargeted tyrosine kinase inhibitors in ovarian cancer.
| Agent | Targets | Phase | Intervention | Stage of the disease | Trial number |
| Sunitinib | VEGFRPDGFRc-kitRETCSF-1Rflt-3 | II | Sunitinib monotherapy | Platinum-resistant recurrent | AGO-OVAR 2.11 | NCT00543049 | (Germany) | II | Sunitinib monotherapy | Recurrent or refractory | DF08-056 | NCT00768144 | (United States) | II | Sunitinib monotherapy | Advanced and/or metastatic | CAN-NCIC-IND185 | NCT00388037 | (Canada) |
| Sorafenib | Raf-1VEGFRPDGFRBflt-3c-kit | II | Sorafenib maintenance versus placebo | CR after standard platinum therapy | NCT00791778 | II | Paclitaxel and carboplatin sorafenib | 1st line | SCRI GYN 19NCT00390611 | II | Paclitaxel and carboplatin sorafenib | Platinum-sensitive recurrent | CASE-CWRU-2804NCT00096200 | II | Topotecan sorafenib | Platinum-resistant recurrent | GYN06-111NCT00526799 |
| Pazopanib | VEGFRPDGFRc-kit | III | Pazopanib maintenance versus placebo | After 1st line chemo | AGO-OVAR16NCT00866697 | II | Pazopanib monotherapy | Recurrent | VEG104450NCT00281632 | I | Metronomic topotecan + pazopanib | Persistent or recurrent | NCT00800345 |
| XL999 | VEGFRPDGFRFGFRflt-3Src | II | XL999 monotherapy | Recurrent | NCT00277290 |
| Motesanib | VEGFRPDGFRc-kit | II | Motesanib monotherapy | Persistent or recurrent | NCT00574951 |
| Vandetanib | VEGFREGFR | II | Docetaxel vandetanib | Persistent or recurrent | SWOG-S0904NCT00872989 | I/II | Pegliposomal doxorubicin vandetanib | Platinum-refractory recurrent | NCT00862836 |
|
|
Studies were accessed from http://www.clinicaltrials.gov/ on May 17, 2009 VEGFR = vascular endothelial growth factor receptor, PDGFR = platelet-derived growth factor receptor,
|